TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01677104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLP-1
Description: GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03261596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
Study: NCT01792830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin.
Study: NCT03076047

Intervention type: DEVICE
Intervention: end-tidal CO2 (ETCO2) monitoring
Description: monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
Study: NCT02657668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Focused Therapy
Description: EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
Study: NCT02848690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care Intervention Group
Description: Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI\> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
Study: NCT03764202

Intervention type: OTHER
Group type: OTHER
Intervention: Detection of sufentanil concentration
Description: * Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point

Intervention type: OTHER
Group type: OTHER
Intervention: Detection of sufentanil concentration
Description: * Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point

Intervention type: OTHER
Group type: OTHER
Intervention: Detection of sufentanil concentration
Description: * Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point

Intervention type: OTHER
Group type: OTHER
Intervention: Detection of sufentanil concentration
Description: * Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point

Intervention type: OTHER
Group type: OTHER
Intervention: Detection of sufentanil concentration
Description: * Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point
Study: NCT04842669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: Endo-laser 422 with interchangeable laser probes will be used for the purpose. It is a 2-channel unit and is software operated. For treatment of small surfaces with mono laser there are diodes of 25, 100 and 500 milliWatt.Frequency will be adjusted to 500 Hz, dose 0.1/cm2 with time duration of 1-5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: (Topical ibuprofen gel) for muscle soreness will be provided
Study: NCT03080038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Sparing Resuscitation Strategy
Description: Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed.
Study: NCT02888002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guide to better alcohol habits
Description: A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guide to better alcohol habits
Description: A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
Study: NCT02250716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
Study: NCT00820079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADX10059 Matching Placebo
Description: oral administration
Study: NCT00518726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008
Description: seasonal influenza vaccine 15ug
Study: NCT00947986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1% Johnson's Baby Shampoo
Description: nasal irrigation 2x a day for 4 weeks
Study: NCT01624168

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Anxiety Management Education
Description: written materials on management of anxiety for self-study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 week tai chi intervention
Description: 10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced tai chi instruction
Description: 10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
Study: NCT03302741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BTX)
Description: Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum neurotoxin (BTX)
Description: Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard BTX injection (ultrasound guided)
Description: For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-dimensional innervation zone (3DIZ) guided injection
Description: Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
Study: NCT00748410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933
Description: 7 days repeat dose
Study: NCT02620618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Infliximab
Description: ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
Study: NCT02964780

Intervention type: PROCEDURE
Intervention: Gastric bypass surgery

Intervention type: BEHAVIORAL
Intervention: Conservative weight loss program
Study: NCT06359054

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F FDG PET/CT
Description: 18F-FDG PET/CT Imaging: Preparation: Participants will be instructed to fast for at least 6 hours before the procedure to ensure low insulin levels and high FDG uptake by cancer cells.~Radiopharmaceutical Administration: Each participant will receive an intravenous injection of 18F-FDG, dosed at approximately 5.2 MBq/kg (0.14 mCi/kg) of body weight.~Imaging Protocol: After the injection, participants will rest in a quiet and dimly lit room for approximately 60 minutes to allow for optimal distribution and uptake of 18F-FDG by the tissues. Subsequently, they will be positioned on the PET/CT scanner bed, and imaging will be performed from the vertex to the proximal thighs. The scan will include a low-dose CT for attenuation correction followed by PET imaging, with the acquisition time adjusted based on the specific protocol (typically 2-3 minutes per bed position).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga DOTATATE PET/CT
Description: 68Ga-DOTATATE PET/CT Imaging: Preparation: No specific fasting is required for 68Ga-DOTATATE PET/CT. However, participants may be advised to hydrate well before the procedure.~Radiopharmaceutical Administration: Participants will receive an intravenous injection of 68Ga-DOTATATE, dosed at approximately 2.2 MBq/kg (0.06 mCi/kg) of body weight.~Imaging Protocol: Similar to the 18F-FDG protocol, after receiving 68Ga-DOTATATE, participants will wait for about 60 minutes to allow for sufficient uptake of the tracer. They will then undergo PET/CT scanning in a supine position, covering the same body regions as the FDG scan. A low-dose CT scan will be conducted first for attenuation correction, followed by the PET scan, with acquisition parameters tailored to the optimal detection of somatostatin receptor expression.
Study: NCT04151550

Intervention type: DEVICE
Group type: OTHER
Intervention: Bilateral Laser Scleral Microporation procedure
Description: Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
Study: NCT00305695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Given IV
Study: NCT02496806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed extract
Description: Treatment capsule containing seaweed extract (treatment)
Study: NCT03433950

Intervention type: OTHER
Intervention: No Intervention
Description: Observational
Study: NCT03056079

Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal aflibercept
Description: Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
Study: NCT03123757

Intervention type: OTHER
Group type: OTHER
Intervention: 6 Minute Walk Test
Description: The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.

Intervention type: OTHER
Group type: OTHER
Intervention: EQ-5D Survey
Description: The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Short Physical Performance Battery
Description: The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
Study: NCT01714739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days.
Study: NCT02052791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study: NCT01525654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support Program
Description: Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
Study: NCT02538835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Description: Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based cognitive therapy, group
Description: Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel \& Segal.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support groups
Description: Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
Study: NCT02866240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal Transcranial Direct Current Stimulation (tDCS).
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
Study: NCT01270490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-gamma, Recombinant
Description: Interferon 50 mcg/m2 to be administered three times per week during two weeks
Study: NCT01697319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
Study: NCT03720613

Intervention type: DRUG
Intervention: Naldemedine
Description: 0.2 mg tablet once a day at any time with or without food

Intervention type: DRUG
Intervention: Lubiprostone
Description: 0.024 mg twice a day \[adjust dose based on liver function\]

Intervention type: DRUG
Intervention: Naloxegol
Description: 25 mg tablet once a day in morning, 1 hour before or 2 hours after food
Study: NCT00132119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene HCl
Description: Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
Study: NCT06749977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remineralization with SAP11-4
Description: The WSL were treated with SAP11-4 according to the manufacturer's instruction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remineralization with sodium fluoride varnish
Description: The WSL were treated with sodium fluoride varnish according to the manufacturer's instruction
Study: NCT00132119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene HCl
Description: Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT02177318

Intervention type: DRUG
Intervention: Spiriva (tiotropium bromide) inhalation capsules
Description: Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
Study: NCT01940003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.